Review



act adoptive cell therapy  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Human Protein Atlas act adoptive cell therapy
    Act Adoptive Cell Therapy, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/act adoptive cell therapy/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    act adoptive cell therapy - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    adoptive cellular therapy act b16f10 cells  (ATCC)
    99
    ATCC adoptive cellular therapy act b16f10 cells
    Day 7 established <t>B16F10</t> tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.
    Adoptive Cellular Therapy Act B16f10 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adoptive cellular therapy act b16f10 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    adoptive cellular therapy act b16f10 cells - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    adoptive t cell therapy act  (ACTGene Inc)
    90
    ACTGene Inc adoptive t cell therapy act
    Day 7 established <t>B16F10</t> tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.
    Adoptive T Cell Therapy Act, supplied by ACTGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adoptive t cell therapy act/product/ACTGene Inc
    Average 90 stars, based on 1 article reviews
    adoptive t cell therapy act - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    adoptive t cell therapy (act)  (Inserm Transfert)
    90
    Inserm Transfert adoptive t cell therapy (act)
    Day 7 established <t>B16F10</t> tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.
    Adoptive T Cell Therapy (Act), supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adoptive t cell therapy (act)/product/Inserm Transfert
    Average 90 stars, based on 1 article reviews
    adoptive t cell therapy (act) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    act adoptive cell therapy  (Human Protein Atlas)
    90
    Human Protein Atlas act adoptive cell therapy
    Day 7 established <t>B16F10</t> tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.
    Act Adoptive Cell Therapy, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/act adoptive cell therapy/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    act adoptive cell therapy - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    adoptive t-cell therapy (act)  (Nature Biotechnology)
    90
    Nature Biotechnology adoptive t-cell therapy (act)
    Day 7 established <t>B16F10</t> tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.
    Adoptive T Cell Therapy (Act), supplied by Nature Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adoptive t-cell therapy (act)/product/Nature Biotechnology
    Average 90 stars, based on 1 article reviews
    adoptive t-cell therapy (act) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Day 7 established B16F10 tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.

    Journal: Cancer immunology research

    Article Title: Modulation of Endoplasmic Reticulum Stress Controls CD4 + T Cell Activation and Anti-tumor Function

    doi: 10.1158/2326-6066.CIR-17-0081

    Figure Lengend Snippet: Day 7 established B16F10 tumors were treated with no T cells, or 2 × 106 TRP T cells cultured in the presence of IP3R inhibitor 2-APB (IP3R TRP) or vehicle control. (A) Tumor growth and (B) survival were measured. Survival endpoints were considered tumor size ≥ 400mm2 with n = 5 mice per group. Experiment was repeated twice. (A) *P < 0.05, 2-tailed Student t test of Control TRP versus IP3RI TRP and (B) **P < 0.001, Log-rank test. (C) Representative flow cytometry plots and quantification of CD4/Vβ14+ splenocytes or (D) CD62L/CD44 phenotype of CD4+/Vβ14+ splenocytes,5 days post adoptive cell therapy. (E) Absolute numbers of CD4+/Vβ14+ T cells in spleens or of (F) CD4+ T cell in tumors 5 days post ACT. (C–F) Data points represent 3 mice per group, *P < 0.05, **P < 0.01 2-tailed Student t test.

    Article Snippet: Adoptive Cellular Therapy (ACT) B16F10 cells were obtained from ATCC and tested negative for mycoplasma in March 2015.

    Techniques: Cell Culture, Control, Flow Cytometry